Physician profile
Michael Stine
NPI 1518101187
$220,378.83
in general payments reported to CMS, 2019-2025
49 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $7,592 · 2021: $22K · 2022: $44K · 2023: $55K · 2024: $58K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $104K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $6,029 · Education: $4,873 · Travel and Lodging: $4,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $103,533.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,500.00 |
| Food and Beverage | $6,028.87 |
| Education | $4,873.35 |
| Travel and Lodging | $4,327.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acessa Health INC. | $93,478.17 | 2021-2025 | Acessa Provu System |
| Baxter Healthcare | $58,110.63 | 2019-2025 | Tisseel, Floseal, Adept |
| Hologic Sales and Service, LLC | $17,963.44 | 2019-2025 | Acessa Provu System, Myosure Tissue Removal Device, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Gynesonics, INC. | $14,151.73 | 2019-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Coopersurgical, INC. | $11,662.40 | 2019-2025 | Endosee, Paragard T 380a, Advincula Delineator Uterine Manipulator |
| Astellas Pharma US INC | $8,832.71 | 2022-2024 | Veozah |
| Abbvie INC. | $7,889.59 | 2019-2025 | Liletta |
| Intuitive Surgical, INC. | $2,599.32 | 2019-2023 | Da Vinci Sp, Da Vinci Surgical System |
| Gen-Probe, INC. | $2,200.00 | 2019-2021 | |
| Merz North America, INC. | $572.08 | 2021-2023 | Xeomin |
| Axonics, INC. | $473.56 | 2021-2023 | Bulkamid, Axonics |
| Therapeuticsmd, INC. | $344.24 | 2019-2021 | |
| Escala Medical INC. | $302.00 | 2025 | |
| Integra Lifesciences Corporation | $227.07 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Pfizer INC. | $208.76 | 2021-2024 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.